TZIELD
TZIELD (Teplizumab-mzwv) is an FDA-approved monoclonal antibody infusion therapy indicated for the delay of clinical type 1 diabetes (T1D) in at-risk individuals. Each single-dose, preservative-free 1×2 mL vial contains Teplizumab-mzwv, formulated for intravenous administration under professional supervision.
Teplizumab works by modulating the immune system, targeting T-cells that attack pancreatic beta cells, thereby slowing the progression of autoimmune destruction and helping to delay the onset of insulin dependence in patients at high risk for type 1 diabetes.
InfusionMed USA, based in Carrollton, Texas, supplies TZIELD and other specialty immunology and endocrine infusion therapies to hospitals, clinics, and specialty infusion centers throughout Dallas, McKinney, Frisco, Plano, Lewisville, The Colony, and surrounding North Texas areas. We ensure cold-chain compliance, proper handling, and timely delivery for licensed healthcare providers.
For professional use only.
Download Form